Frei Julia, Jarzebska Natalia T, Mellett Mark, Kündig Thomas M, Pascolo Steve, Reichmuth Andreas M
Department of Dermatology, University Hospital Zurich (USZ), University of Zurich (UZH), Zurich, Switzerland.
Faculty of Medicine, University of Zurich, Zurich, Switzerland.
Methods Mol Biol. 2024;2786:205-215. doi: 10.1007/978-1-0716-3770-8_9.
The recent success of the synthetic mRNA-based anti-COVID-19 vaccines has demonstrated the broad potential of the mRNA platform for applications in medicine, thanks to the combined efforts of a small community that has vastly improved key determinants such as design and formulation of synthetic mRNA during the past three decades. However, the cost of production and sensitivity to enzymatic degradation are still limiting the broader application of synthetic mRNA for therapeutic applications. The increased interest in mRNA-based technologies has spurred a renaissance for circular RNA (circRNA), as the lack of free 5' and 3' ends substantially increases resistance against enzymatic degradation in biological systems and does not require expensive cap analogs, as translation is controlled by an Internal Ribosome Entry Site (IRES) sequence. Thus, it can be expected that circRNA will play an important role for future mRNA therapeutics. Here we provide a detailed guide to the production of synthetic circRNA.
基于合成信使核糖核酸(mRNA)的抗新冠病毒疫苗最近取得的成功,证明了mRNA平台在医学应用方面具有广阔潜力,这得益于一个小群体在过去三十年里的共同努力,他们极大地改进了诸如合成mRNA的设计和配方等关键决定因素。然而,生产成本和对酶促降解的敏感性仍然限制了合成mRNA在治疗应用中的更广泛应用。对基于mRNA的技术兴趣的增加,刺激了环状RNA(circRNA)的复兴,因为缺乏游离的5'和3'末端,大大增加了其在生物系统中对酶促降解的抗性,并且不需要昂贵的帽类似物,因为翻译由内部核糖体进入位点(IRES)序列控制。因此,可以预期circRNA将在未来的mRNA治疗中发挥重要作用。在此,我们提供了一份关于合成circRNA生产的详细指南。